Conference
7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)
Authors
Chi KN; Hotte SJ; Yu E; Tu D; Eigl B; Tannock I; Saad F; North S; Powers J; Eisenhauer E
Volume
7
Publisher
Elsevier
Publication Date
September 1, 2009
DOI
10.1016/s1359-6349(09)71382-5
Conference proceedings
European Journal of Cancer Supplements
Issue
2
ISSN
1359-6349